Products developed under the collaboration may include either monoclonal antibodies or antibodies linked to potent cell-killing payloads utilizing Seattle Genetics’ antibody-drug-conjugate (ADC) technology.
“We’re pleased that Seattle Genetics has elected to move forward with this antigen,” said Kathy Ordonez, president of Celera Genomics. “With a strong combination of proprietary technology and practical experience, Seattle Genetics provides a promising opportunity for development of antibodies or ADCs based on our cancer targets.”
In this multi-year agreement, Celera Genomics and Seattle Genetics are jointly designating a number of cell-surface proteins discovered and validated through Celera Genomics’ proprietary proteomic platform as antigen targets. Seattle Genetics is carrying out initial screening to generate and select the appropriate corresponding antibodies or ADCs for joint development and commercialization.
Celera Genomics and Seattle Genetics will co-fund preclinical and clinical product development and will share any profits resulting from collaboration products.